Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing o...
Group sales grow by 1%1 at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarter Excluding COVID-...
Agilent Technologies Inc. announced the company’s near and long-term targets for reaching net-zero greenhouse gas emissions have been approved by the...
Sales revenue in constant currencies down 16.4 percent, excluding Covid-19-related business down slightly above 10 percent; underlying EBITDA marg...
Dr. Ali will be spearheading all aspects of MHTC’s operations, ensuring its commitment to facilitating and promoting the nation’s healthcare tr...
Kasim Kutay, CEO of Novo Holdings, said: “With her extensive market knowledge and executive experience in the pharmaceutical and life science industr...
Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with IS...
In a rapidly evolving world where scientific breakthroughs are essential for the betterment of healthcare, MoleculeAI stands at the forefront, pioneering t...
Second-Quarter 2023 Revenues of $12.7 Billion Expected Decline in Paxlovid and Comirnaty(1) Revenues Drove 53% Operational D...
"While market trends during the quarter, especially in biopharma, were more challenging than anticipated, we leveraged the Avantor Business System ...
One in Four American Adults Would Rather Not Know They Have Cancer A new study from The Harris Poll, commissioned by Bayer, suggests fear factors ...
Highlights: Reported revenue of $1.67 billion declined 2.7% year-over-year, and decreased 2.3% on a core(1) basis. GAAP net income of $111 millio...
Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 Shipped 109 NovaSeq X instruments i...
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and prov...
© 2024 Biopharma Boardroom. All Rights Reserved.
